# Danazol

Source: https://onco.cc/drugs/danazol/  
OnCo record `danazol` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Danazol is an old hormone tablet, licensed for endometriosis, that can raise haemoglobin and platelets in myelofibrosis and bone marrow failure. It was the comparison treatment that momelotinib beat in the MOMENTUM trial.

## Summary

Danazol is a synthetic androgen licensed since the 1970s for endometriosis, fibrocystic breast disease and hereditary angioedema. In haematology it is used off-label for the anaemia of myelofibrosis and myelodysplastic syndromes and for immune and aplastic cytopenias, where about a third of patients improve; it also lengthens telomeres in telomere-biology disorders.

In the phase 3 MOMENTUM trial in symptomatic, anaemic myelofibrosis previously treated with a JAK inhibitor, danazol was the active comparator: 25 percent of patients on momelotinib had their symptom score halve against 9 percent on danazol, and more became transfusion independent. Liver toxicity, virilisation and thrombosis limit its use. The primary myelofibrosis page names it among the treatments for anaemia.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-09-17
- Also known as: Danol
- Tags: subtype-drugs-wave
- Brand: Danocrine
- Modality: Oral synthetic androgen (hormonal agent)
- Mechanism: A weak androgen derived from ethisterone that stimulates erythropoiesis and thrombopoiesis, in part by raising telomerase activity in haematopoietic cells, and suppresses gonadotropins.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Danazol
- Wikipedia: https://en.wikipedia.org/wiki/Danazol

## Connected records

- drugs: [Momelotinib](https://onco.cc/drugs/momelotinib/)
- cancers: [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)

---
JSON: https://onco.cc/api/v1/entities/danazol.json